We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

54 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

8.8% more ownership

Funds ownership: 69.77% → 78.57% (+8.8%)

2% more funds holding

Funds holding: 53 → 54 (+1)

11% less capital invested

Capital invested by funds: $428M → $379M (-$48.7M)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.96%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
11
Increased
20
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$5.11M
2
BCM
Burrage Capital Management
Massachusetts
+$4.07M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.19M
4
BlackRock
BlackRock
New York
+$3.09M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.3M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$5.16M
2
APM
Avidity Partners Management
Texas
-$1.24M
3
RSCM
Rock Springs Capital Management
Maryland
-$1.18M
4
MF
Magnetar Financial
Illinois
-$633K
5
CA
CHI Advisors
New York
-$327K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
51
Bank of America
North Carolina
$4K -$7.34K -308 -63%
RFA
52
Reilly Financial Advisors
California
$2K +$2.38K +100 New
Daiwa Securities Group
53
Daiwa Securities Group
Japan
$1K +$1.05K +44 New
AIG
54
American International Group
New York
$98 -$3.24K -136 -3%
SFM
55
Sphera Funds Management
Israel
– -$5.16M -196,411 Closed
Millennium Management
56
Millennium Management
New York
– -$1.06K -40,164 Closed
MF
57
Magnetar Financial
Illinois
– -$633K -24,075 Closed
Marshall Wace
58
Marshall Wace
United Kingdom
– -$326K -12,418 Closed
SFI
59
Susquehanna Fundamental Investments
Pennsylvania
– -$288K -10,955 Closed
ZP
60
Zimmer Partners
New York
– -$263K -10,000 Closed
MWNA
61
Marshall Wace North America
New York
– -$250K -9,514 Closed
State of Tennessee, Department of Treasury
62
State of Tennessee, Department of Treasury
Tennessee
– -$238K -9,044 Closed
Susquehanna International Group
63
Susquehanna International Group
Pennsylvania
– -$223K -8,469 Closed
UBS Group
64
UBS Group
Switzerland
– -$14K -536 Closed
1 2
3

INZY Hedge Fund Activity: Q4 2020 in Review

54 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2020, worth a combined $379M — down 11% from $428M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new INZY positions and 10 closed out — a net gain of 1 holder — while 20 added to existing stakes and 7 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $5.11M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.16M sold.

  • 54 institutional investors held Inozyme Pharma (INZY) as of Q4 2020, up from 53 in Q3 2020.
  • Funds reported $379M of Inozyme Pharma stock for Q4 2020, down 11% quarter-over-quarter.
  • 11 funds opened new Inozyme Pharma positions in Q4 2020 and 10 closed out, a net change of +1 holder.
  • The largest Inozyme Pharma buyer in Q4 2020 was Suvretta Capital Management, an estimated $5.11M added.
  • The largest Inozyme Pharma seller in Q4 2020 was Sphera Funds Management, an estimated $5.16M sold.

Based on aggregated 13F filings for Q4 2020.